Oragenics Faces Potential NYSE American Delisting Over Equity Standards

Oragenics, Inc. (NYSE American: OGEN) received a deficiency letter from NYSE American on August 26, 2026, for non-compliance with listing standards related to stockholders' equity. The company has 45 days to submit a plan to regain compliance to avoid potential delisting.